Clinical trials

Only want trials near your city that fit you? Get alerts

Disease

Country

Status

Phase

Reset

416 trials

NCT07166445
Recruiting
Deep Learning for Automated Discrimination Between Stage T1-T2 and T3 Renal Cell Carcinoma on Contrast-Enhanced CT
Not applicable · China · 1 site
Registry update: 10 Sept 2025
NCT06676527
Recruiting
Vorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell Carcinoma
Not applicable · China · 1 site
Registry update: 5 Dec 2025
NCT06582017
Recruiting
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Phase 1 · United States · 11 sites
Registry update: 20 Oct 2026
NCT06362369
Recruiting
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
Phase 1/2 · United States · 5 sites
Registry update: 13 Apr 2026
NCT06116461
Recruiting
Nivolumab dose optimization in patients with a complete, partial or stable response (NIVOPTIMIZE-trial)
Phase 4 · Netherlands · 2 sites
Registry update: 15 Aug 2024
NCT06447103
Recruiting
An Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the Detection of Recurrent Clear Cell Renal Cell Cancer After Surgery Comparing Carbonic Anhydrase IX (CAIX) PET CT to Conventional PET CT for Post-Op Staging in Kidney Cancer
Phase 2 · United States · 1 site
Registry update: 15 Jun 2026
NCT06519760
Recruiting
68Ga-C1 PET/ CT Imaging in Clear Cell Renal Cell Carcinoma
Not applicable · China · 1 site
Registry update: 7 Nov 2024
NCT06553339
Recruiting
A Study of HS-10516 in Patients With VHL Syndrome Associated Tumors
Phase 1 · China · 1 site
Registry update: 14 Aug 2024
NCT06380816
Recruiting
A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer
Phase 1/2 · United Kingdom · 4 sites
Registry update: 8 May 2026
NCT06536439
Recruiting
Planning Operative Strategy Using a Digital Renal Artery Clamping Tool
Not applicable · Belgium · 5 sites
Registry update: 1 Apr 2025
NCT06769893
Recruiting
A Study Evaluating the Value of 68Ga-NOTA-RCCB6 PET Imaging for Targeting CD70 in the Clinical Staging, Therapeutic Evaluation, and Restaging of Renal Cell Carcinoma, and Comparing It with 68Ga-PSMA PET/CT Imaging
Not applicable · China · 1 site
Registry update: 10 Jan 2025
NCT06239194
Recruiting
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
Phase 1/2 · United States · 6 sites
Registry update: 15 Oct 2026
NCT06332755
Recruiting
Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC
Phase 1 · United States · 1 site
Registry update: 24 Nov 2025
NCT06690697
Recruiting
Combination of Toripalimab and JS004 Therapy for ccRCC
Phase 2 · China · 1 site
Registry update: 15 Nov 2024
NCT06514651
Recruiting
Study to evaluate the safety of MAQ-001 as monotherapy and combination therapy in patients with advanced cancers
Phase 1 · France · 4 sites
Registry update: 18 Mar 2026
NCT06379698
Recruiting
Rein 3D PRINT PERSONALIZE
Not applicable · France · 1 site
Registry update: 22 Jun 2025
NCT04715191
Recruiting
Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
Phase 1 · United States · 1 site
Registry update: 6 Aug 2026
NCT06451497
Recruiting
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
Phase 1 · United States · 3 sites
Registry update: 2 Apr 2026
NCT06265285
Recruiting
Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
Phase 2 · United States · 1 site
Registry update: 2 Oct 2026
NCT06234605
Recruiting
A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma
Phase 1 · United States · 21 sites
Registry update: 2 Oct 2026

Ordered by registry start date. Freshness and sponsorship never change the order.